NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller [Yahoo! Finance]
enGene Holdings Inc. (ENGN)
Company Research
Source: Yahoo! Finance
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a relatively recent addition to the 13F portfolio of Duquesne Capital. The fund first disclosed a stake in the company in the third quarter of 2024. This position comprised over 280,000 shares. In the coming quarters, the fund gradually built up this position. In the first quarter of 2025, it improved the position by 178%. In the second quarter of 2025, the holding was increased by another 4%. In the third quarter of 2025, share ownership rose to nearly 1.9 million, up 131% compared to filings for the previous quarter. Filings for the fourth quarter of 2025 show that the fund owned more than 3 million shares in the firm, up nearly 60% compared to filings for the previous quarter. READ ALSO: Billionaire Ken Fisher's 15 Most Notable Moves for 2026 Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? In recent years, the smart money has positioned itself for a multi-billion dollar transformation of the car
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene (ENGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ENGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
- enGene (ENGN) is now covered by WBB Securities. They set a "buy" rating and a $21.50 price target on the stock.MarketBeat
- enGene (ENGN) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- enGene Announces Name Change to enGene Therapeutics Inc.Business Wire
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of CarePR Newswire
ENGN
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 424B5
- 3/9/26 - Form 8-K
- ENGN's page on the SEC website